Biomarin Pharmaceutical (BMRN) Capital Expenditures (2009 - 2026)

Biomarin Pharmaceutical's Capital Expenditures history runs 18 years deep, the most recent figure standing at $20.9 million for Q1 2026.

• Quarterly Capital Expenditures rose 24.78% year-over-year to $20.9 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $107.2 million (up 40.88% YoY) and the FY2025 annual result came in at $103.0 million, up 20.62% from the prior year.
• Capital Expenditures was $20.9 million for Q1 2026 at Biomarin Pharmaceutical, down from $40.7 million in the prior quarter.
• Across five years, Capital Expenditures topped out at $133.1 million in Q4 2022 and bottomed at -$38.0 million in Q2 2022.
• A 5-year average of $21.3 million and a median of $20.9 million in 2026 frame the typical range for Capital Expenditures.
• Annual changes were most pronounced in 2022 — Capital Expenditures tumbled 510.85% — and 2023, when it jumped 2178.17%.
• Biomarin Pharmaceutical's Capital Expenditures stood at $133.1 million in 2022, then slumped by 127.52% to -$36.6 million in 2023, then jumped by 153.32% to $19.5 million in 2024, then jumped by 108.51% to $40.7 million in 2025, then slumped by 48.62% to $20.9 million in 2026.
• Business Quant data shows BMRN's Capital Expenditures at $20.9 million in Q1 2026, $40.7 million in Q4 2025, and $48.8 million in Q3 2025.